Clorox (CLX) Earnings Date & Reports

Key Takeaways

• Net sales rose 33% year over year to $1.91 billion, topping analyst consensus, with the GOJO (Purell) acquisition contributing roughly 15 points of growth.
• Adjusted EPS (earnings per share) surged 82% to $1.55, well above the roughly $1.07 Wall Street estimate.
• GAAP (Generally Accepted Accounting Principles) diluted EPS was $1.39, up from $0.65 in the year-ago quarter.
• Gross margin contracted 130 basis points to 40.4%, pressured by higher commodity, manufacturing and logistics costs.
• Management kept its full-year adjusted EPS outlook of $5.70 to $6.00 but now expects results to land closer to the low end of the range.
• For more details on Clorox's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages.
• Discover new trade ideas and market opportunities with Trending AI Robots.

Earnings Context and Why It Matters

Clorox's first-quarter fiscal 2027 results, covering the period ended September 30, 2026, mark a pivotal checkpoint in the company's post-digital-transformation and acquisition strategy. The quarter reflects the first full integration of GOJO, the maker of Purell, which closed in April 2026 and has shifted Clorox's portfolio further toward health and wellness. It also laps a year-ago period depressed by an inventory drawdown tied to the company's U.S. ERP (Enterprise Resource Planning) system transition. Investors are watching whether the top-line lift from GOJO and a recovering base business can outpace mounting input-cost inflation, and whether Clorox can rebuild margins while holding onto hard-won market share.

Reported Results

Clorox reported net sales of $1.91 billion, up 33% from the prior-year quarter and ahead of the roughly $1.88 billion consensus. Organic sales increased 18%, reflecting the benefit of lapping the ERP transition-related inventory drawdown in the year-ago quarter. GOJO contributed approximately 15 points to total sales growth.

GAAP diluted EPS was $1.39, a 114% increase from $0.65 a year earlier. Adjusted EPS, a non-GAAP measure that excludes acquisition and integration costs, rose 82% to $1.55, comfortably exceeding the roughly $1.07 analyst estimate. The beat was driven by higher net sales, cost savings and a lower tax rate, partially offset by higher commodity, manufacturing and logistics costs.

Gross margin, however, declined 130 basis points to 40.4% from 41.7%, reflecting inflationary headwinds and GOJO integration expenses. By segment, Health and Wellness sales rose 62% (with GOJO adding about 39 points), Household rose 17%, Lifestyle rose 16%, and International rose 11%, including 9% organic growth.

For the full year, the company maintained its adjusted EPS outlook of $5.70 to $6.00 and its net sales growth guidance of 13% to 14%, but lowered its gross margin expectation to about 41.5% and now anticipates adjusted EPS results closer to the low end of the range.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates and market opportunities more efficiently than manual screening. For investors tracking names like Clorox, it offers a structured way to surface setups across the consumer staples sector and beyond.

Market Reaction and Investor Sentiment

Heading into the report, sentiment was cautiously optimistic, with analysts bracing for a steep year-over-year recovery driven by the GOJO deal and the ERP comparison lap. The outsized adjusted EPS beat, roughly 48 cents above consensus, underscored the strength of the top-line rebound, while the 33% sales jump validated the strategic rationale behind the Purell acquisition. At the same time, the market is likely to weigh the guidance nuance carefully: management kept its full-year adjusted EPS range intact but signaled results are now expected closer to the low end, citing a more challenging cost environment. That combination of strong current-quarter momentum and softer margin expectations is a key driver of how investors interpret the stock's next move.

Forward Outlook and Key Factors to Monitor

Looking ahead, the central theme is whether Clorox can rebuild profitability while sustaining the consumption and market-share momentum it has begun to show. Management expects full-year organic sales growth of about 3.5% to 4.5%, though that includes more than 3.5 points of benefit from lapping the prior-year ERP-related drawdown, implying underlying growth that is roughly flat to slightly positive.

On costs, the company is leaning on productivity and cost savings, which reached one of the highest quarterly levels on record, while planning targeted pricing and revenue-growth-management actions that are expected to phase in more heavily during the back half of the fiscal year. Gross margin is now projected at about 41.5% for the year, reflecting higher-than-normal inflation and negative mix.

Investors should monitor commodity and logistics cost trends, the pace of GOJO integration and synergies under the combined Clorox Purell ProCare business, interest expense tied to the debt-financed acquisition, and whether pricing actions can offset input-cost pressure without sacrificing share gains. Category demand and consumer value-seeking behavior will also remain important signposts as the year progresses.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations